You can watch Cellectis and buy or sell other stocks, options, and ETFs commission-free!
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France. The listed name for CLLS is Cellectis S.A. American Depositary Shares.
52 Week High
52 Week Low
— per share
Expected Mar 3, After Hours